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Figure 1. Total number of CD4+ Treg and Tem cells in the syngeneic vs. allogeneic recipients. Shown are total number of CD4+ Treg and Tem cells in the graft (day 0),
and at subsequent time points following AHSCT for syngeneic (syn) recipients, identical host recipient pairs; and allogeneic (allo) recipients, with minor antigen
mismatch between host and donor with resultant cGVHD induction. Day+14 is a time point early post AHSCT, while day +28 represents well-established cGVHD.
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uted to target rather than non-target tissues. Target sites of
cGVHD (skin, gut and liver) had several fold greater num-
ber of Tem cells compared to controls both early and late in
disease. The number of Tem cells in target sites was
maintained as cGVHD progressed, and the Treg to Tem ratio
in target tissues was signiﬁcantly lower than that of the
controls at all times. Cell division of Tem and Treg cells was
high in the liver, and remained high for the Treg cells as
disease progressed. Meanwhile, Treg cells underwent
faster loss from the liver, likely due to cell death given that
the total number of Treg cells did not change. Our ﬁndings
shed light on in vivo behavior of Treg and Tem cells, T cell
subtypes critical to the biology of cGVHD. Furthermore, our
methodology will be translated to investigate in vivo T cell
kinetics in patients undergoing AHSCT as deuterated water
labeling is safe, not toxic and non-radioactive.475
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Ocular chronic GVHD (cGVHD) is one of the most bother-
some and common long-term complications after allogeneic
HCT. The 2005 NIH cGVHD Consensus Project provided
expert recommendations for diagnosis: dry, gritty, or painful
eyes, cicatricial conjunctivitis, keratoconjunctivitis sicca or
conﬂuent areas of punctate keratopathy in conjunction with
abnormally low Schirmer’s tear test. However these have not
been prospectively validated in patients. The goal of this
analysis was to identify predictive models for ocular cGVHD
diagnosis, disease activity and clinical correlates that could
be feasibly employed by transplant clinicians to assess out-
comes in clinical practice and therapeutic trials. Between2004 and 2013, 210 patients with moderate (n¼57) or severe
(n¼151) cGVHD were enrolled on the NIH/NCI cGVHD cross-
sectional observational study (NCT00092235). Median time
from cGVHD diagnosis to enrollment was 765 (20-6670)
days. Patient-reported outcomes (PROs) and transplant-
clinician-reported outcomes (ClinROs) were gathered:
Schirmer’s, NIH eye score (0-3), Lee cGVHD symptom scale
(dry eye, needs eye drops frequently, and difﬁculty seeing
clearly) (each 0-4) and chief eye symptom intensity scale (0-
10). Participants were examined by ophthalmologists expe-
rienced in diagnosing and treating ocular cGVHD (MBD, RJB),
who conﬁrmed the diagnosis and classiﬁed patients as active
vs. inactive. Univariate analyses and logistic models were
developed to examine the associations among ophthalmol-
ogist assessment, PRO and ClinRO measures. Based on
ophthalmology evaluation, 157 (75%) patients were diag-
nosed with ocular cGVHD; a majority (133/157; 85%) had
active disease. In a multivariable model, the NIH eye score (3
vs. 2 vs.1) (p<0.0001) and lower Schirmer’s (p<0.0001) were
signiﬁcant independent predictors of ocular cGVHD (sensi-
tivity 93.0%, speciﬁcity 92.2%). The Lee dry eye was the
strongest predictor of active ocular cGVHD (p<0.0001)
(sensitivity 68.5%, speciﬁcity 82.6%). The following risk fac-
tors for ocular cGVHD were identiﬁed: related donor
(p¼0.0029) and HLA matched (p¼0.0095) HCT. Oral cGVHD
was strongly associated with the diagnosis of ocular cGVHD
(p<0.0001). NIH eye score and Schirmer’s test are ClinRO
measures that are strongly predictive for diagnosis of ocular
cGVHD, while a single PRO item assessing dry eye symptom
bother had 82.6% speciﬁcity for ocular cGVHD activity. Re-
sults support the use of these items for routine screening and
ocular triage when providing long-term care to allogeneic
HCT survivors. Prospective studies are needed to determine if
a single PRO item assessing dry eye is sufﬁcient for use as a
trial outcome and to guide therapeutic decision-making in
clinical practice. We conﬁrm observations of others that
HLA-matched and related donor transplants are associated
with an increased risk of ocular cGVHD.476
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The pathophysiology of chronic Graft-versus-Host Disease
(cGVHD) is complex and poorly understood. Storage of pe-
ripheral blood mononucleated cells (PBMC) for research in
patient cohorts is vital. However, conventional peripheral
blood draws are often insufﬁcient for larger scale immu-
nology studies; in particular, cGVHD patients are frequently
lymphopenic, which further limits an ability to study the role
of relatively rare populations such as Treg cells. To address
this limitation, we evaluated the safety of collecting large
quantities of lymphocytes in cGVHD patients by steady-state
peripheral blood leukapheresis. In total, 132 patients with
cGVHD underwent PBMC collection for research purposes via
leukapheresis performed from 2004 to 2014 on NCI cGVHD
Natural History Protocol, NCT00092235. Various apheresis
machines were used, namely: Baxter CS3000 (n¼63, 47%),
Haemonetics MCS-P (n¼18, 14%), and Terumo SPECTRA
(n¼52, 39%). Median whole blood/anticoagulant (ACDA) ra-
tio was 12:1; median whole blood ﬂow rate (WBFR) was 60
ml/min (35-85); and median product volume was 147 ml
(59-450). Median age was 50 years (18-68). NIH cGVHD
Global scores were moderate (n¼46, 35%) or severe (n¼82,
62%). Mean absolute circulating PBMC level pre-leukaphe-
resis was 2.4 K/mL (0.3-11.6). 22 patients (17%) had an abso-
lute lymphocyte count <1.0 K/ml. A subset of patients (17/
132) had sufﬁciently low pre-leukapheresis peripheral
counts that required special approval for the procedure (Hb
<9.0 g/dL, n¼3; WBC < 3.0 K/mL, n¼5; platelets < 120 K/mL,
n¼9). A two-arm continuous ﬂow apheresis procedure was
used in 108 patients (81%) whereas a one-arm procedurewas
used in 25 patients (8%). Only nine patients underwent leu-
kapheresis via central venous catheter (the remainder were
pheresed using peripheral access). 94 (71%) achieved the
goal collection of 2 x 109 PBMCs, with a mean volume pro-
cessed of 4.6 L. Median total run time was 88 minutes. Mean
number of cells collected and efﬁciencies were: (1) lym-
phocytes, 3.7 x 109, 66.5%; (2) monocytes, 1.1 x 109, 51.1%;
and (3) PBMCs: 4.8 x 109, 59.7%. Mild decreases in abso-
lute peripheral counts were observed, including (median
change 1 hour post-leukapheresis; each value signiﬁcant,
p<0.0001): Hgb: -8%; Plt: -22%; lymphocytes: -26%; and
monocytes: -17%. Grade 1 AEs (CTCAE v4.03) were experi-
enced by 21 patients (16%): hypotension (n¼1, 1%), oral
dysesthesia (n¼10, 8%), paresthesias (n¼6, 5%), anxiety (n¼1,
1%), localized bleeding (n¼2, 2%), and nausea (n¼1, 1%). In
conclusion, we found that steady-state PBMC leukapheresis
represents a safe and effective method for collecting high
numbers of immune cells in patients with moderate-to-se-
vere cGVHD.Wider utilization of leukapheresis in the cGVHD
setting should accelerate immunology research into the
pathogenesis of cGVHD, particularly relating to the role of
relatively rare cell populations.477
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Allogeneic blood and marrow transplantation for the treat-
ment of hematologic malignancies continues to be plaguedby complications such as chronic graft-versus-host disease
(cGVHD), which can occur in upwards of 50% of patients.
Standard therapy involves corticosteroid administration,
which is not always effective and impedes the patient’s re-
turn to a completely competent immune system, thus
increasing the risk of infectious complications. Extracorpo-
real photopheresis (ECP) has been successfully used to abate
cGVHD symptoms in many patients. The effect this therapy
has on lymphocyte subsets in the reconstituting immune
compartment has yet to be fully ascertained. In the pre-
sent study, we used ﬂow cytometric analysis to examine
lymphocyte subsets in patients undergoing ECP for the
treatment of cGVHD. Peripheral blood was collected from 5
patients prior to starting ECP and after 90 days of treatment.
CD4+T cell populations were analyzed for expression of
CD45RA and CCR7 to classify naïve (RA+, CCR7+), central
memory (TCM; RA-, CCR7+), effector memory (TEM; RA-,
CCR7-), and terminally differentiated effector memory
(TEMRA; RA+, CCR7-) T cells. The data reported supports pre-
vious studies which show that all CD4+ T cell populations
analyzed are altered in cGVHD patients (n¼11) compared to
healthy controls (n¼5). In particular, CD4+ TCM and naïve cells
were decreased in cGVHD patients, while CD4+ TEM and
TEMRA were elevated in these patients. Analysis of the same
subsets in cGVHD patients after 90 days of ECP treatment
revealed that the percentage of CD4+ TCMincreased above
baseline levels in the 5 cGVHD patients examined, while
CD4+ TEMRA were decreased during the same time frame. The
increase in CD4+ TCM and the decrease in CD4+ TEMRA were
statistically signiﬁcant as determined by the paired Student’s
t test. Additionally, the ratio of CD4+ TCM to TEM and CD4+ TCM
to TEMRA was calculated in patients before and after ECP
treatment. Results indicate signiﬁcantly increased ratios of
both TCM:TEMand CD4+ TCM:TEMRA in these patients as well.
This data strongly supports the role of ECP in the normali-
zation of CD4+ T cell populations in cGVHD patients.478
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While the ﬁrst-in-disease trials of GvHD prevention with
costimulation blockade add CTLA4-Ig to standard tacrolimus/
methotrexate, previous work has suggested that mTOR in-
hibition with sirolimus is more pro-tolerogenic when paired
with costimulation blockade. We have now investigated
combination CTLA4-Ig + sirolimus to prevent GvHD in the
NHP model, and have interrogated the outcomes using a
systems-based approach. Our experiments provide strong
clinical, immunologic and trancriptomic evidence for potent
synergy when CTLA4-Ig and sirolimus are combined for
GvHD prevention.
We determined the impact of the following treatments on
GvHD after haplo-identical HSCT: 1) no therapy (n¼4) 2)
CTLA4-Ig monotherapy (using belatacept, n¼3) 3) sirolimus
monotherapy (n¼4) 4) combination belatacept and
sirolimus (n¼3). To determine the relative impact of each
therapeutic approach, we monitored clinical GvHD, GvHD-
free survival, and ﬂow cytometric signs of immune activation
